在便秘占主导地位和混合型刺激性肠综合征中的便微生物群特征
Mariya Gryaznova1, Yuliya Smirnova1, Inna Burakova1
1Laboratory of Metagenomics and Food Biotechnology, Voronezh State University of Engineering Technologies, 394036 Voronezh, Russia.
Microorganisms
|July 27, 2024
概括
这项研究分析了患有刺激性肠综合征 (IBS) 的患者的肠道微生物群,发现细菌多样性的改变和特定的微生物转移. 几种新型细菌物种与IBS亚型有关,为这种情况提供了新的见解.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 人类健康 人类健康 人类健康
背景情况:
- 刺激性肠综合征 (IBS) 显著影响患者的生活方式.
- 肠道微生物组的改变与IBS有关,但机制尚不清楚.
- 这项研究侧重于便秘占主导地位的IBS (IBS-C) 和混合型IBS (IBS-M) 的便微生物组.
研究的目的:
- 在患有IBS-C和IBS-M的患者中调查便微生物组合.
- 为了确定与IBS亚型相关的特定微生物变化.
- 探索IBS背后潜在的微生物机制.
主要方法:
- 分析了IBS患者和健康对照组的便样本.
- 16S rRNA的V3区域使用Ion Torrent PGM平台进行了测序.
- 评估了微生物组的组成和多样性.
主要成果:
- 与健康个体相比,在IBS-C和IBS-M患者中观察到α和β多样性的增加.
- 这两种IBS亚型都呈现出高的Firmicutes/Bacteroidetes比率.
- 在IBS患者中发现了Actinobacteria和Verrucomicrobiota的丰富性增加.
结论:
- 这项研究是首次将特定的细菌,包括Turicibacter sanguinis和Parabacteroides merdae与IBS亚型联系起来.
- 对于IBS-C和IBS-M,已经确定了不同的微生物特征.
- 这些发现有助于理解肠道微生物群在IBS病变发生中的作用.
相关概念视频
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
154
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
154
01:17Irritable Bowel Syndrome I: Introduction
264
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
264
01:21Drugs for Treatment of Constipation-Predominant IBS
151
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
151
01:17Chronic Bowel Disorders: Introduction
436
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
436
01:17Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
160
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
160